Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular basis for reduced cleavage activity and drug resistance in D30N HIV-1 protease.

Journal of biomolecular structure & dynamics - 1 Jan 2022

Bihani Subhash C, Gupta Gagan Deep, Hosur Madhusoodan V

Abstract excerpt

Nelfinavir is one of the FDA-approved HIV-1 protease inhibitors and a part of highly active anti-retroviral therapy (HAART) for the treatment of HIV-AIDS. Nelfinavir was the first HIV-1 protease inhibitor to be approved as a paediatric formulation. The application of HAART had resulted in significant improvement in the lives of AIDS patients. However, the emergence of drug resistance in HIV-1 protease has limited...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acquired Immunodeficiency Syndrome
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Mutation

Share to Nelfinavir

Source

Identifiers

PMID: 34609269
DOI: 10.1080/07391102.2021.1982007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular basis for reduced cleavage activity and drug resistance in D30N HIV-1 protease.PMID 34609269Read ↗

Molecular Basis for Reduced Cleavage Activity and Drug Resistance in D30N HIV-1 proteaseSemantic proximity Read ↗

Insights into the interaction mechanism of first-generation HIV-1 protease inhibitors with wild-type and mutant (D30N and L76V) enzymes through in-silico based approach.Semantic proximity Read ↗

Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.Semantic proximity Read ↗

Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.Semantic proximity Read ↗

How Mutations Can Resist Drug Binding yet Keep HIV-1 Protease Functional.Semantic proximity Read ↗

Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S.Semantic proximity Read ↗

Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.Semantic proximity Read ↗

Comprehending the Structure, Dynamics, and Mechanism of Action of Drug-Resistant HIV ProteaseSemantic proximity Read ↗

HIV Protease: Historical Perspective and Current ResearchSemantic proximity Read ↗

Drug Resistance Mechanism of L10F, L10F/N88S and L90M mutations in CRF01_AE HIV-1 protease: Molecular dynamics simulations and binding free energy calculations.Semantic proximity Read ↗

Computational characterization of structural role of the non-active site mutation M36I of human immunodeficiency virus type 1 protease.Semantic proximity Read ↗

Elasticity-Associated Functionality and Inhibition of the HIV Protease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.